PRECIGEN, INC. Acquisitions, Net of Cash Acquired
PRECIGEN, INC. (PGEN) reported Acquisitions, Net of Cash Acquired of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2021-03-01
- PRECIGEN, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2018-12-31 was $920.00K.
- PRECIGEN, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2018-09-30 was $0.00.
- PRECIGEN, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2017-12-31 was $0.00.
- PRECIGEN, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2017-09-30 was $0.00.
- PRECIGEN, INC. payments to acquire businesses, net of cash acquired for fiscal 2020 was $0.00.
- PRECIGEN, INC. payments to acquire businesses, net of cash acquired for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- PRECIGEN, INC. payments to acquire businesses, net of cash acquired for fiscal 2018 was $920.00K.
- PRECIGEN, INC. payments to acquire businesses, net of cash acquired for fiscal 2017 was -$2.05M.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 6 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month | Payments to Acquire Businesses, Net of Cash Acquired 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-01 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-01 | |||
| 2018-12-31 | $920.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $920.00K derived: sum of 2 quarters · filed 2021-03-01 | $920.00K 10-K · filed 2021-03-01 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $0.00 10-Q · filed 2018-11-08 | ||
| 2018-06-30 | $0.00 10-Q · filed 2018-08-13 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | -$2.05M 10-K · filed 2020-03-02 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$2.05M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | -$2.05M 10-Q · filed 2018-08-13 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $0.00 derived: sum of 2 quarters · filed 2019-03-01 | $0.00 derived: sum of 3 quarters · filed 2019-03-01 | $0.00 10-K · filed 2019-03-01 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $0.00 derived: sum of 2 quarters · filed 2017-11-09 | $0.00 10-Q · filed 2017-11-09 | $9.45M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $0.00 10-Q · filed 2017-08-09 | $9.45M derived: sum of 3 quarters · filed 2018-03-01 | $84.43M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-10 | $9.45M derived: sum of 2 quarters · filed 2018-03-01 | $84.43M derived: sum of 3 quarters · filed 2018-03-01 | $94.37M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $9.45M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $84.43M derived: sum of 2 quarters · filed 2018-03-01 | $94.37M derived: sum of 3 quarters · filed 2018-03-01 | $123.93M 10-K · filed 2018-03-01 |
| 2015-09-30 | $74.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $84.92M derived: sum of 2 quarters · filed 2016-11-09 | $114.48M 10-Q · filed 2016-11-09 | $114.94M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $9.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $39.50M 10-Q · filed 2016-08-09 | $39.96M derived: sum of 3 quarters · filed 2017-03-01 | $102.17M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $29.56M 10-Q · filed 2016-05-10 | $30.02M derived: sum of 2 quarters · filed 2017-03-01 | $92.22M derived: sum of 3 quarters · filed 2017-03-01 | $92.22M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $460.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $62.66M derived: sum of 2 quarters · filed 2017-03-01 | $62.66M derived: sum of 3 quarters · filed 2017-03-01 | $67.58M 10-K · filed 2017-03-01 |
| 2014-09-30 | $62.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $62.20M derived: sum of 2 quarters · filed 2015-11-09 | $67.12M 10-Q · filed 2015-11-09 | $67.11M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $4.91M 10-Q · filed 2015-08-10 | $4.91M derived: sum of 3 quarters · filed 2016-02-29 | $4.91M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $4.91M 10-Q · filed 2015-05-11 | $4.91M derived: sum of 2 quarters · filed 2016-02-29 | $4.91M derived: sum of 3 quarters · filed 2016-02-29 | $4.91M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | -$5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$5.00K derived: sum of 2 quarters · filed 2016-02-29 | -$5.00K derived: sum of 3 quarters · filed 2016-02-29 | -$517.00K 10-K · filed 2016-02-29 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $0.00 derived: sum of 2 quarters · filed 2014-11-13 | -$512.00K 10-Q · filed 2014-11-13 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | -$512.00K 10-Q · filed 2014-08-14 | ||
| 2013-03-31 | -$512.00K 10-Q · filed 2014-05-09 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-03-02 | |||
| 2011-12-31 | $28.66M 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |